Written Question · S2W-01120 · Session 2
Further to the answer to question S2W-735 by Malcolm Chisholm on 23 June 2003, what steps it will take to refer the drug cefuroxime to NHS …
The question
To ask the Scottish Executive, further to the answer to question S2W-735 by Malcolm Chisholm on 23 June 2003, what steps it will take to refer the drug cefuroxime to NHS Quality Improvement Scotland in order to commission research into the drug's effectiveness in the treatment of MRSA, ensure full investigation of its performance to date in the treatment of prior, or existing, cases of MRSA and, until such time as the investigation is completed, issue guidelines on the use of cefuroxime in future cases.
The answer
It would be inappropriate to refer cefuroxime to NHS Quality Improvement Scotland. Cefuroxime is not generally recommended as a treatment for MRSA, and its use in patients with MRSA would normally be avoided. An exception to this might be that a patient was suffering from a second infectious organism, sensitive to cefuroxime, which might justify its use.The Scottish Executive is undertaking work to improve antimicrobial prescribing. One of the aims is to reduce the creation of drug-resistant bacterial strains such as MRSA. The Scottish Medicines Consortium, facilitated by NHS Quality Improvement Scotland is assisting in taking this work forward.
In the Official Report
No contribution in the Official Report cites S2W-01120 by reference.